| 摘要 |
New compounds having the general formula (I), as well as their pharmacologically acceptable addition salts with acids, are disclosed. In the formula (I), either (Ia) R11 stands for a hydrogen atom in the .beta. position, whereas R12 and R13each represent a hydrogen atom, or (Ib) R11 stands for a hydrogen atom in the .beta. position, whereas R12 and R13 together represent a second bond, or (Ic) R11 and R12 together represent a second bond, whereas R13 stands for a hydrogen atom, or (Id) R11 stands for a hydrogen atom in the .alpha. position, whereas R12 and R13 together represent a second bond. In all cases (Ia, Ib, Ic, or Id), X stands for an oxygen atom, the hydroxymino grouping > N ? OH or two hydrogen atoms, R1 stands for a hydrogen atom or a methyl group; R2 stands for a hydroxy group, a C1-C10 alkoxy or C1 C10 acyloxy group, whereas R3 and R4 have the usual meanings for competitive pregesterone antagonists, given in the description. Also disclosed are processes for producing these new compounds, pharmaceutical compositions containing these compounds, their use to produce medicaments and new intermediate products required for the process. These new compounds have a strong affinity for the gestagen receptor, as well as strong antigestagenous, antiglucorticoidal, antimineralcorticoidal and antiandrogenous properties.
|
